Skip to content
Govbase

Policy-Driven News

Govbase
Congress·In Committee·H.R. 7837

Rep. Meuser Introduces Most Favored Patient Act to Tie U.S. Drug Prices to Lower International Rates

Most Favored Patient Act of 2026

9 days ago·View on Congress.gov

Legislative Progress

House
Senate
President
Law

Key Points

  • This bill would limit the amount Medicare and Medicaid pay for many prescription drugs. The price would be capped at the second-lowest price paid for that same drug in a group of eight other countries, including Canada, France, and the United Kingdom.
  • The policy would help millions of seniors and low-income Americans by lowering the cost of medications they get at the pharmacy or have administered by a doctor, such as cancer treatments or specialized injections.
  • Drug companies could avoid these strict price caps if they sign a special agreement with the government. To do this, they must agree to the lower prices and also commit to creating more manufacturing jobs within the United States.
  • This plan is designed to address the fact that Americans often pay significantly more for the exact same medications than people in other wealthy nations.
  • If the bill becomes law, the government would start testing this new pricing system on January 1, 2029, and the program would last for five years.
HealthcareEconomy Finance

Impact Analysis

Personal Impact

Scores: 1 = low, 5 = highSentiment: -5 to +5 (net benefit)

Milestones

2 milestones2 actions
Mar 5, 2026House

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Mar 5, 2026

Introduced in House

Source Information

Document Type

Congressional Bill

Official Title

Most Favored Patient Act of 2026

Bill NumberHR 7837
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsor

Analysis generated by AI. Always verify with official sources.